# A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough

> **NCT03979638** · PHASE2 · TERMINATED · sponsor: **Bellus Health Inc. - a GSK company** · enrollment: 68 (actual)

## Conditions studied

- Chronic Refractory Cough

## Interventions

- **DRUG:** BLU-5937
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03979638
- **Lead sponsor:** Bellus Health Inc. - a GSK company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-07-10
- **Primary completion:** 2020-04-23
- **Final completion:** 2020-04-23
- **Target enrollment:** 68 (ACTUAL)
- **Why stopped:** Trial was terminated due to the impact of the COVID-19 on trial activities. 68 patients with refractory chronic cough were enrolled with 52 completing treatment
- **Last updated:** 2021-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03979638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03979638, "A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03979638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*